Verastem Inc  

(Public, NASDAQ:VSTM)   Watch this stock  
0.00 (0.00%)
Aug 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.05 - 4.67
Open     -
Vol / Avg. 0.00/1.59M
Mkt cap 119.86M
P/E     -
Div/yield     -
EPS -1.24
Shares 36.99M
Beta 2.25
Inst. own 30%
Nov 6, 2017
Q3 2017 Verastem Inc Earnings Release (Estimated) Add to calendar
Aug 8, 2017
Q2 2017 Verastem Inc Earnings Release
Jun 9, 2017
Verastem Inc at Jefferies Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -78.05% -37.05%
Return on average equity -99.15% -41.70%
Employees 32 -
CDP Score - -


117 Kendrick St Ste 500
NEEDHAM, MA 02494-2730
United States - Map
+1-781-2924200 (Phone)
+1-914-9499618 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Officers and directors

Robert Forrester President, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Julie B. Feder Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Daniel W. Paterson Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
Joseph Chiapponi Vice President - Finance
Age: 48
Bio & Compensation  - Reuters
Monica Kleinman Vice President, General Counsel
Age: 34
Bio & Compensation  - Reuters
Michael Ferraresso Vice President - Commercial Operations
Bio & Compensation  - Reuters
Lori A. Kunkel M.D. Clinical and Scientific Advisory Board
Age: 59
Bio & Compensation  - Reuters
Hagop Youssoufian M.Sc., M.D., Head - Hematology and Oncology Development
Age: 59
Bio & Compensation  - Reuters
Michael G. Kauffman M.D. Ph.D. Lead Independent Director
Age: 52
Bio & Compensation  - Reuters
Eric K. Rowinsky M.D. Director
Age: 60
Bio & Compensation  - Reuters